Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Caribou Biosciences (CRBU) Total Liabilities: 2019-2024

Historic Total Liabilities for Caribou Biosciences (CRBU) over the last 6 years, with Dec 2024 value amounting to $60.4 million.

  • Caribou Biosciences' Total Liabilities fell 15.83% to $53.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $53.1 million, marking a year-over-year decrease of 15.83%. This contributed to the annual value of $60.4 million for FY2024, which is 5.40% down from last year.
  • According to the latest figures from FY2024, Caribou Biosciences' Total Liabilities is $60.4 million, which was down 5.40% from $63.8 million recorded in FY2023.
  • Over the past 5 years, Caribou Biosciences' Total Liabilities peaked at $72.9 million during FY2022, and registered a low of $18.2 million during FY2020.
  • Moreover, its 3-year median value for Total Liabilities was $63.8 million (2023), whereas its average is $65.7 million.
  • In the last 5 years, Caribou Biosciences' Total Liabilities surged by 343.33% in 2020 and then fell by 12.46% in 2023.
  • Caribou Biosciences' Total Liabilities (Yearly) stood at $18.2 million in 2020, then spiked by 200.28% to $54.5 million in 2021, then soared by 33.67% to $72.9 million in 2022, then dropped by 12.46% to $63.8 million in 2023, then decreased by 5.40% to $60.4 million in 2024.